Popular semaglutide-based drugs used for weight loss may reduce chronic and acute pain, which could make them a promising ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

Ozempic and Wegovy are both weekly injections with semaglutide. While the former is approved to treat Type 2 diabetes, the ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Ro details dietary choices that may help Wegovy's capacity to regulate appetite and foster a healthier weight as well as ...